Compare Deckers Outdoor Corp (DECK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Recursion Pharmaceuticals Inc — how do they compare? Deckers Outdoor Corp trades at $106.98 (market cap $14.97B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.75B). The key difference: Deckers Outdoor Corp is far larger — about 8.6× Recursion Pharmaceuticals Inc's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| DECK | RXRX | |
|---|---|---|
Market Cap | $14.97B | $1.75B |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $6.79 |
52-Week Low | $79.54 | $2.84 |
Enterprise Value | $13.44B | $1.17B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
